Sugi Predict

Sugi Predict / Compounds / SCHEMBL3358680

SCHEMBL3358680

SCHEMBL3358680

Nc1c(C(=O)O)ccc(Br)c1Cl

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ G6PD P11413 1/20 0.42
▸ CASP7 P55210 1/20 0.42
▸ CASP6 P55212 1/20 0.42
▸ KDM4E B2RXH2 3/20 0.41
▸ CYP3A4 P08684 2/20 0.41
▸ GLA P06280 1/20 0.41
▸ MAPT P10636 4/20 0.41
▸ GAA P10253 2/20 0.41
▸ TSHR P16473 2/20 0.39
▸ CASP1 P29466 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ ALDH1A1 P00352 5/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ THRB P10828 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ RECQL P46063 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3667246 0.79 TSHR (0.52) G6PDCASP7CASP6KDM4ECYP3A4
SCHEMBL2422463 0.79 CASP7 (0.45) G6PDCASP7CASP6KDM4ECYP3A4
SCHEMBL24558234 0.78 ABL1 (0.51) CASP7KDM4ECYP3A4GLAMAPT
SCHEMBL30111088 0.78 ABL1 (0.51) CASP7KDM4ECYP3A4GLAMAPT
SCHEMBL2962331 0.78 CASP7 (0.48) G6PDCASP7CASP6KDM4ECYP3A4
SCHEMBL30776108 0.78 CYP1A2 (0.41) TSHRCASP1SMN1; SMN2CYP1A2ALDH1A1
SCHEMBL27659849 0.78 CYP1A2 (0.41) TSHRCASP1SMN1; SMN2CYP1A2ALDH1A1
SCHEMBL6887635 0.78 SELL (0.48) KDM4EMAPTTSHRCASP1SMN1; SMN2
SCHEMBL7778429 0.76 CYP3A4 (0.46) G6PDCASP7CASP6KDM4ECYP3A4
SCHEMBL7308399 0.76 KDM4E (0.46) G6PDCASP7CASP6KDM4ECYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12441727-B2 Tricyclic compounds as inhibitors of KRAS INCYTE CORPORATION (US) 2025-10-14 — — US disclosed
EP-4565574-A1 SARS-COV2 MAIN PROTEASE INHIBITORS GILEAD SCIENCES, INC. (US) 2025-06-11 — — EP disclosed
US-12029739-B2 SHP2 inhibitor and use thereof KANAPH THERAPEUTICS INC. (KR) 2024-07-09 — — US disclosed
US-12029739-B2 SHP2 inhibitor and use thereof KANAPH THERAPEUTICS INC. (KR) 2024-07-09 — — US disclosed
EP-4367117-A1 TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS Incyte Corporation (US) 2024-05-15 — — EP disclosed
US-20240140957-A1 BRIDGED COMPOUNDS AS KRAS G12D INHIBITOR AND DEGRADER AND THE USE THEREOF BEONE MEDICINES I GMBH (CH) 2024-05-02 — — US disclosed
CN-117881680-A Tricyclic compounds as KRAS inhibitors 因赛特公司 2024-04-12 — — CN disclosed
US-20240059710-A1 KRAS G12D Inhibitors JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2024-02-22 — — US disclosed
WO-2024031089-A1 SARS-COV2 MAIN PROTEASE INHIBITORS GILEAD SCIENCES, INC. (US) 2024-02-08 — — WO disclosed
US-20240025918-A1 KRAS G12D Inhibitors JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2024-01-25 — — US disclosed
US-20150239900-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC 2015-08-27 — — US disclosed
WO-2015054572-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2015-04-16 — — WO disclosed
US-8829502-B2 Condensed polycyclic compound and organic light emitting element including the same CANON KABUSHIKI KAISHA (JP) 2014-09-09 — — US disclosed
US-20130048965-A1 CONDENSED POLYCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT INCLUDING THE SAME CANON KABUSHIKI KAISHA (JP) 2013-02-28 — — US disclosed
WO-2010056758-A1 QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS FENG YANGBO (US) 2010-05-20 — — WO disclosed
EP-0781767-B1 Process for producing isatoic anhydrides SUMITOMO CHEMICAL CO (JP) 2001-09-05 — — EP disclosed
US-5981749-A Process for producing isatoic anhydrides SUMITOMO CHEMICAL COMPANY LIMITED (JP) 1999-11-09 — — US disclosed
US-5973145-A Process for producing isatoic anhydrides SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1999-10-26 — — US disclosed
US-5795984-A Process for producing isatoic anhydrides SUMITOMO CHEMICAL COMPANY LIMITED (JP) 1998-08-18 — — US disclosed
EP-0781767-A1 Process for producing isatoic anhydrides SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1997-07-02 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240059710-A1 KRAS G12D Inhibitors KRAS, NRAS, HRAS G6PD 1690/4885CASP7 1003/4885CASP6 2637/4885
US-12441727-B2 Tricyclic compounds as inhibitors of KRAS KRAS, NRAS, HRAS G6PD 985/4885CASP7 1922/4885CASP6 2269/4885
US-20130048965-A1 CONDENSED POLYCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT INCLUDING THE SAME CCNE2, NFE2L2, CRY2 G6PD 3415/4885CASP7 3785/4885CASP6 3447/4885
US-20150239900-A1 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS G6PD 3221/4885CASP7 3244/4885CASP6 3720/4885
US-20240140957-A1 BRIDGED COMPOUNDS AS KRAS G12D INHIBITOR AND DEGRADER AND THE USE THEREOF KRAS, NRAS, G3BP1 G6PD 1365/4885CASP7 2288/4885CASP6 2016/4885
US-12029739-B2 SHP2 inhibitor and use thereof PTPN1, PTPN5, PTPN2 G6PD 783/4885CASP7 3590/4885CASP6 3385/4885
US-20240025918-A1 KRAS G12D Inhibitors KRAS, NRAS, HRAS G6PD 2678/4885CASP7 1371/4885CASP6 2827/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.